FDA declares nationwide EpiPen shortage due to manufacturing delays

  • FDA declares nationwide EpiPen shortage due to manufacturing delays

FDA declares nationwide EpiPen shortage due to manufacturing delays

FARE suggested patients who are having difficulty finding the EpiPen of their choice due to the shortage should speak to their physicians about obtaining a description for a different auto-injector.

Mylan warned US customers on Tuesday that they may have trouble getting EpiPen prescriptions filled due to problems at a factory. Mylan is expediting shipment to wholesalers upon receipt, and supply levels may vary across wholesalers and pharmacies.

The Food and Drug Administration announced on Wednesday there are temporary shortages of EpiPens, they contain the drug used to treat severe allergic reactions to things like peanuts and bee stings.

This was Mylan's first acknowledgment of possible United States supply issues following reports of EpiPen shortages in Canada and Britain last month.

Mylan, the company that manufactures EpiPen, says the shortage is due to manufacturing delays. She said the agency "is committed to working closely with the manufacturers to resolve the shortage as quickly as possible".

'The FDA is not getting that from the pharma companies'.

Pfizer said it was overcoming the manufacturing problems, saying it was increasing production. The manufacturer blames supply and distribution issues. Earnings for the latest quarter rose to $87.1 million, or 17 cents per share, from $66.4 million, or 12 cents per share in the year-earlier period.

"It;s of serious concern because a lot of times these are lifesaving medications people need them right now". Overall revenue in the quarter was $2.68 billion, the company said, missing analysts' expectations for $2.74 billion. The drugmaker has 2,500 products in its pipeline and has turned to developing complex generic products and biosimilars, or copycat versions of biotechnology medicines, to make up for weakness in other parts of its portfolio.

Mylan, the second-biggest generic drug manufacturer by sales, is faced with an industrywide pattern of depressed sales of U.S. generic drugs and headwinds from competitive pricing.

A pharmacist holds a package of EpiPen epinephrine auto-injectors.